4007787550
|
 |
||||||||||||||
| 貨號 | 品名 | 規(guī)格 | 包裝 | 單價 | 貨期 | 庫存 |
| JD200512101328 | Abatacept | 99.00% | 5mg | 19600元 | 咨詢客服 | 3天 |
| JD200512101308 | Abatacept | 99.00% | 1mg | 11000元 | 咨詢客服 | 3天 |
| 性狀： | Abatacept (CTLA4lg) 是一種可溶性融合蛋白，由人 CTLA4 的胞外結構域和人 IgG1 Fc 部分的片段 (鉸鏈，CH2 和 3 結構域) 組成。Abatacept 是選擇性 T 細胞共刺激調節(jié)劑，也是一種用于自身免疫性疾病的蛋白藥物。 |
| 質量標準： | Storage Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Description Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains)[1]. Abatacept is a selective T-cell co-stimulation modulator and a protein drug for the autoimmune diseases[2]. |
| 貯存： | Storage Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month References [1]. Kiykim A, et al. Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency. J Allergy Clin Immunol Pract. 2019 Jun 22. [2]. Lon HK, et al. Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach. J Pharmacokinet Pharmacodyn. 2013 Dec;40(6):701-12. [3]. Patakas A, et al. Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigen-Presenting Cells. Arthritis Rheumatol. 2016 Mar;68(3):627-38. |
